圣诺生物公告，股东川发投资拟减持不超过4721578股，占公司总股本的3%；副总经理卢昌亮拟减持不 超过96579股，占公司总股本的0.0614%；董事、副总经理王晓莉拟减持不超过574696股，占公司总股 本的0.3652%。减持期间为2025年9月15日至12月14日。 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-024 成都圣诺生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 8 月 22 日(星期五) 至 2025 年 8 月 28 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱(snkj@snbiopharm.com)进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 成都圣诺生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 15 日在上海证券交易所网站（www.sse.com.cn）披露公司《2025 年半年度报告》， 为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况， 公司计划于 2025 年 8 月 29 日下午 13:00-14:00 举行 20 ...

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Group 1 - The core viewpoint of the news is that the A-share market saw a collective rise in weight-loss drug concept stocks, driven by the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1][2]. - Han Yu Pharmaceutical (300199) experienced a significant increase of over 14%, while other companies like Jin Kai Biotechnology and Shengnuo Bio rose by over 12% and 6% respectively [1][2]. - Novo Nordisk's stock rose over 6% in after-hours trading following the FDA's announcement regarding Wegovy [1]. Group 2 - The following companies showed notable stock performance: - Han Yu Pharmaceutical (300199) with a rise of 14.66% and a total market value of 26.4 billion [2]. - Jin Kai Biotechnology (301509) increased by 12.28% with a market value of 5.1 billion [2]. - Shengnuo Bio (688117) rose by 6.00% and has a market value of 7.229 billion [2]. - Yangguang Nuohuo (688621) increased by 4.37% with a market value of 8.96 billion [2]. - ST Nuotai (688076) rose by 4.08% with a market value of 15 billion [2]. - Other companies like Zhongsheng Pharmaceutical and Kangyuan Pharmaceutical also saw increases close to 4% [1][2].

Group 1 - The core viewpoint of the news is that the A-share market's weight-loss drug concept stocks have collectively risen due to the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1] - Han Yu Pharmaceutical saw a significant increase of over 14%, while Jin Kai Biotechnology and Sheng Nuo Bio both rose by over 12% and 6% respectively [1] - The approval of Wegovy is expected to positively impact Novo Nordisk, which saw its stock rise over 6% in after-hours trading [1] Group 2 - The following are the stock performance details of key companies in the weight-loss drug sector: - Han Yu Pharmaceutical: 14.66% increase, market cap of 26.4 billion [2] - Jin Kai Biotechnology: 12.28% increase, market cap of 5.1 billion [2] - Sheng Nuo Bio: 6.00% increase, market cap of 7.229 billion [2] - Yang Guang Nuo He: 4.37% increase, market cap of 8.96 billion [2] - ST Nuo Tai: 4.08% increase, market cap of 15 billion [2] - Zhong Sheng Pharmaceutical: 3.99% increase, market cap of 19.9 billion [2] - Kang Yuan Pharmaceutical: 3.97% increase, market cap of 10.4 billion [2]

Group 1 - The core point of the article is that the FDA has accelerated the approval of Wegovy (2.4 mg semaglutide) for treating moderate to severe liver fibrosis in adult patients with non-alcoholic steatohepatitis (NASH), leading to significant stock price increases for several pharmaceutical companies [1] Group 2 - Hanyu Pharmaceutical's stock rose over 10% following the news [1] - Companies such as Sunlight Novo and Jinkai Biotechnology saw stock increases of over 5% [1] - Novo Nordisk's stock rose over 6% in after-hours trading in the US market due to the FDA announcement [1]

事件：2025年8 月 14 日，公司发布《2025 年半年度报告》。2025 年 H1公司实现营业收入3.38 亿元， 同比增长69.69%；实现归母净利润0.89 亿元，同比增长308.29%；实现扣非归母净利润0.89 亿元，同比 增长367.92%；实现经营活动现金流净额0.82 亿元，同比增长213.22%。单季度来看，2025年Q2 公司实 现营业收入1.53 亿元，同比增长61.50%；实现归母净利润0.42 亿元，同比增长687.09%；实现扣非归母 净利润0.42 亿元，同比增长982.84%。 点评： 受益于多肽产业链景气度，原料药业务和CDMO 业务同比高增长。 1）原料药业务：2025 年H1 公司原料药业务收入1.89 亿元，同比增长232.38%，主要得益于司美格鲁 肽、替尔泊肽出口销售增加；截至2025 年中报，公司已拥有21 个自主研发的多肽类原料药品种，在国 内市场公司取得14 个品种多肽原料药生产批件或激活备案，在国外市场公司取得11 个品种获得美国 DMF 备案。公司加快原料药国际注册、申报步伐，优化在美国、欧盟、韩国、俄罗斯等国家和地区的 产品布局，打造全球范围内有竞争 ...

Group 1 - The core viewpoint of the report highlights that Shengnuo Biotech (688117.SH) benefits from the favorable conditions in the peptide industry chain, leading to significant year-on-year growth in its raw material drug business and CDMO (Contract Development and Manufacturing Organization) business [2] - The company's capacity construction is becoming increasingly complete, indicating outstanding medium to long-term growth potential [2] Group 2 - The report mentions potential risks, including the possibility of new orders falling short of expectations, fluctuations in raw material drug prices, and risks associated with geopolitical and tariff changes [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating that the stock price is expected to outperform the benchmark index by more than 15% [13]. Core Views - The company is benefiting from the favorable conditions in the peptide industry chain, with significant growth in both its active pharmaceutical ingredient (API) and Contract Development and Manufacturing Organization (CDMO) businesses [2][3]. - The company has achieved impressive financial results in the first half of 2025, with a revenue of 338 million yuan, a year-on-year increase of 69.69%, and a net profit attributable to shareholders of 89 million yuan, up 308.29% [1][2]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 338 million yuan, a net profit of 89 million yuan, and a net cash flow from operating activities of 82 million yuan, reflecting year-on-year growth rates of 69.69%, 308.29%, and 213.22% respectively [1]. - For Q2 2025, the company achieved a revenue of 153 million yuan and a net profit of 42 million yuan, with year-on-year growth rates of 61.50% and 687.09% respectively [1]. Business Segments - The API business generated 189 million yuan in revenue in H1 2025, marking a year-on-year increase of 232.38%, driven by increased exports of Semaglutide and Tirzepatide [2]. - The CDMO business reported revenue of 42 million yuan in H1 2025, a growth of 72.93%, primarily due to the advancement of a clinical project for a client [3]. Capacity Expansion - The company has successfully launched a new production line for peptide APIs with an annual capacity of 395 kg and has made significant progress in its CDMO and API industrialization projects [4][5]. - The company is expected to benefit from the completion of new production lines, alleviating previous capacity constraints and enhancing its growth potential in the peptide industry [5]. Earnings Forecast - The company is projected to achieve revenues of 751 million yuan, 990 million yuan, and 1.21 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits of 191 million yuan, 273 million yuan, and 349 million yuan [7].

（文章来源：证券日报） 证券日报网讯 8月14日晚间，圣诺生物发布公告称，2025年半年度公司实现营业收入337，569，910.26 元，同比增长69.69%；归属于上市公司股东的净利润为88，956，694.45元，同比增长308.29%。 ...